These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21557881)

  • 21. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.
    Papakostas GI; Perlis RH; Scalia MJ; Petersen TJ; Fava M
    J Clin Psychopharmacol; 2006 Feb; 26(1):56-60. PubMed ID: 16415707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies.
    Furukawa TA; Cipriani A; Atkinson LZ; Leucht S; Ogawa Y; Takeshima N; Hayasaka Y; Chaimani A; Salanti G
    Lancet Psychiatry; 2016 Nov; 3(11):1059-1066. PubMed ID: 27726982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differing antidepressant maintenance methodologies.
    Safer DJ
    Contemp Clin Trials; 2017 Oct; 61():87-95. PubMed ID: 28739537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
    Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
    Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of patient selection and study characteristics on signal detection in placebo-controlled trials with antidepressants.
    Mancini M; Wade AG; Perugi G; Lenox-Smith A; Schacht A
    J Psychiatr Res; 2014 Apr; 51():21-9. PubMed ID: 24462042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
    Bridge JA; Iyengar S; Salary CB; Barbe RP; Birmaher B; Pincus HA; Ren L; Brent DA
    JAMA; 2007 Apr; 297(15):1683-96. PubMed ID: 17440145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-frequency repetitive transcranial magnetic stimulation accelerates and enhances the clinical response to antidepressants in major depression: a meta-analysis of randomized, double-blind, and sham-controlled trials.
    Berlim MT; Van den Eynde F; Daskalakis ZJ
    J Clin Psychiatry; 2013 Feb; 74(2):e122-9. PubMed ID: 23473357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of placebo rates in major depressive disorder trials.
    Stolk P; Ten Berg MJ; Hemels ME; Einarson TR
    Ann Pharmacother; 2003 Dec; 37(12):1891-9. PubMed ID: 14632596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antidepressant treatment history and drug-placebo separation in a placebo-controlled trial in major depressive disorder.
    Hunter AM; Cook IA; Tartter M; Sharma SK; Disse GD; Leuchter AF
    Psychopharmacology (Berl); 2015 Oct; 232(20):3833-40. PubMed ID: 26319158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis.
    Feeney A; Hock RS; Fava M; Hernández Ortiz JM; Iovieno N; Papakostas GI
    J Affect Disord; 2022 May; 305():55-64. PubMed ID: 35247482
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of placebo response in bipolar depression.
    Nierenberg AA; Østergaard SD; Iovieno N; Walker RS; Fava M; Papakostas GI
    Int Clin Psychopharmacol; 2015 Mar; 30(2):59-66. PubMed ID: 25438027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Placebo Response in Pediatric Anxiety Disorders: Implications for Clinical Trial Design and Interpretation.
    Dobson ET; Strawn JR
    J Child Adolesc Psychopharmacol; 2016 Oct; 26(8):686-693. PubMed ID: 27027330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
    Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
    Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs.
    Merlo-Pich E; Alexander RC; Fava M; Gomeni R
    Clin Pharmacol Ther; 2010 Nov; 88(5):634-42. PubMed ID: 20861834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.
    Sinyor M; Schaffer A; Smart KA; Levitt AJ; Lanctôt KL; Grysman NH
    J Clin Psychiatry; 2012 Feb; 73(2):e277-87. PubMed ID: 22401489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.